・Correlation of the Blood Test Results Obtained between Assays Using Microliter-scale Fingertip Blood Samples Collected with a Novel Blood Collection Device and Conventional Venous Blood Assays
KEIO JOURNAL OF MDECINE，DOI: 10.2302/kjm.2017-0009-OA
Kagawa Prefectural Chuo Hospital and Okayama University Hospital, under the guidance of MD Takaguchi, a specialist of liver internal medicine from Japan, are conducting clinical research on type B and C hepatitis C testing using our blood collection device.
Local governments in Japan have initiated the ""Know Hepatitis Project"" to promote hepatitis countermeasures, but there are still many undiagnosed patients.
We aim to realize an accurate screening test by simple fingertip blood collection anywhere in the city without the need to go to public health centers or medical institutions.
At the World Health Organization's (WHO) annual meeting (May 28, 2016), 194 member countries unanimously adopted a strategy for eradicating viral hepatitis by 2030 and declared that measures will be taken on a global scale. With the goal of eradicating hepatitis B and C viruses (HBV, HCV) by 2030, they will try to reduce the number of deaths annually by 65%, raise the number of treatments by 80%, and save 7.1 million people through prevention and treatment. The number of deaths due to hepatitis is 1.5 million every year, exceeding the number of deaths due to HIV, tuberculosis or malaria. At the background of this eradication declaration are the recent appearance of HCV drugs with high cure rate and HBV vaccines and effective therapeutic agents.
New Cancer screeing tests, more specialized test items, genetic tests, etc., that can be tested using a small amount of serum separated in the laboratory as a sample, can be outsourced the testing to an external specialized organization via the laboratory.
|13 items of Lifestyle Related Diseases||Liver Function||Total Protein (TP)||To detect protein disorder|
|Albumin (ALB)||To detect nutritional status of the body, etc.|
|Aspartate Aminotransferase (AST)||To detect abnormality in liver function and heart function|
|Alanine Aminotransferase (ALT)||To detect liver function, especially degeneration of hepatocytes|
|Gamma-Glutamyl Transferase (γ-GTP)||To detect liver function, especially alcoholic liver damage|
|Lipid metabolism||Total Cholesterol (TC)||To detect risk of arteriosclerosis|
|Triglycerides (TG)||To detect risk of fatty liver, arteriosclerosis, etc.|
|High Density Lipoprotein (HDL-C)||To detect risk of arteriosclerosis to combine with LDL-Cholesterol|
|Low Density Lipoprotein (LDL-C)||To detect risk of arteriosclerosis|
|Kidney Function||Blood Urea Nitrogen (BUN)||To detect abnormality in kidney function|
|Creatine (CRE)||To detect abnormality in kidney function|
|Uric Acid||Uric Acid (UA)||To detect risk of gout Glycometabolism|
|Glycometabolism||HbA1c (NGSP) Hemoglobin A1c||To detect risk of diabetes in average blood sugar level for last 3 months|
|Tumor Marker For Men||Carcinoembryonic Antigen (CEA)||Screening for digestive system cancer|
|Prostate Specific Antigen (PSA)||Screening for prostate cancer|
|Alpha Fetoprotein (AFP)||Screening for liver cancer|
|Pancreatic Cancer (CA19-9)||Screening for pancreatic cancer, biliary cancer, gallbladder cancer|
|Tumor Marker For Women||Carcinoembryonic Antigen (CEA)||Screening for digestive system cancer|
|Metastatic Breast Cancer (CA15-3)||Screening for metastatic breast cancer and ovarian cancer|
|Ovarian Cancer (CA125)||Screening for ovarian cancer and uterine cancer|
|CA19-9 Pancreatic Cancer (CA19-9)||Screening for pancreatic cancer, biliary cancer, gallbladder cancer|